GlassScriptPhysician profile
Richard Edwards
NPI 1689794133
$2,257.14
in general payments reported to CMS, 2019-2025
24 companies · $404 in 2025
The $404 reported for 2025 was more than what 90% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $439 · 2023: $609 · 2024: $499 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $540.15 | 2021-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Merck Sharp & Dohme LLC | $334.50 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $203.51 | 2021-2025 | Doc Band |
| Corium, LLC | $159.67 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $152.63 | 2022-2025 | Bexsero, Rotarix, Penmenvy |
| Sanofi Pasteur INC. | $112.64 | 2024-2025 | |
| Kaleo, INC. | $104.86 | 2021-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $87.68 | 2021-2022 | |
| Phadia US INC. | $85.47 | 2022-2025 | Immunocap |
| Pfizer INC. | $83.86 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $55.10 | 2023 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $51.32 | 2023-2024 | Ycanth |
| Cepheid | $40.35 | 2023 | Genexpert |
| Collegium Pharmaceutical, INC. | $32.10 | 2025 | Jornay Pm |
| Qol Medical, LLC | $30.46 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $24.07 | 2024 | Relexxii |
| Organon LLC | $23.80 | 2025 | |
| Abbvie INC. | $23.05 | 2021 | |
| Ironwood Pharmaceuticals, INC | $22.97 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $22.11 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.33 | 2024 | Zoryve |
| Supernus Pharmaceuticals, INC. | $18.08 | 2024 | Qelbree |
| Seqirus USA INC | $15.76 | 2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $14.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.